Kardigan, Inc. announced a director or officer change; made a public disclosure
SEC 8-KRead source ↗
Kardigan, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders3 buying, 0 selling3 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds67 adding, 0 cuttingOf 27 active managers that changed their stake, 27 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 350% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Kardigan, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Short interest rising. Shares sold short rose 106% in a month to 6.7% of tradable shares.
Latest results
- Earnings per share
- -$2.89 against an average estimate of -$0.64: missed by 350.5%
- Share reaction
- +3.3% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
- Next report
- November 9, 2026; average EPS estimate -$1.04
Price chart
- 1 day+0.6%
- 1 week+12.5%
- 1 month-3.9%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 11, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Leadership
- Results
Kardigan, Inc. reported results
SEC 8-KRead source ↗
No model value for Kardigan, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 9, 2026, before the open. Analysts expect revenue of $0 and EPS of −$1.04 (range −$2.34 to −$0.69) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.29 | — | $333330 | — |
| Next | −$4.12 | +4% | $500000 | +50% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +46.8% on 90 days ago. In the last 30 days, 0 analysts raised Kardigan, Inc.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.92 | −$3.01 |
| 60 days ago | −$4.54 | −$3.20 |
| 30 days ago | −$4.54 | −$3.20 |
| 7 days ago | −$4.43 | −$4.17 |
| Now | −$4.29 | −$4.12 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.64 | −$2.89 | −350.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 6.7% of tradable shares
- Days to cover
- 5.75 at average volume
- Short interest, 1 month
- +106% to October 15, 2026
- Held by institutions
- 78% of shares
- Held by insiders
- 15.6% of shares
- Employees
- 241 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −12.3%
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Share price after results
- Next day
- 1 up, 0 down typical move ±3.3%
- After a week
- 0 up, 1 down typical move ±0.8%
- After a month
- 0 up, 1 down typical move ±11.3%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 11, 2026 | +3.3% | −0.1% | −0.8% | −11.3% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $1.4B
- Institutions reporting
- 69
- Positions opened / closed
- 67 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Hrtg Gpe, LLC | $403M | 16.9M | 29.5% | — |
| FMR LLC | $212M | 8.9M | 15.5% | — |
| Perceptive Advisors LLC | $196M | 8.2M | 14.3% | — |
| T. Rowe Price Investment Management, Inc. | $100M | 4.2M | 7.3% | — |
| Capital Research Global Investors | $85.8M | 3.6M | 6.3% | — |
| Jpmorgan Chase & Co | $46.4M | 1.8M | 3.4% | — |
| Alliancebernstein L.P. | $36.6M | 1.5M | 2.7% | — |
| Liberty Mutual Group Asset Management Inc. | $28.5M | 1.2M | 2.1% | — |
| Jennison Associates LLC | $21.6M | 904K | 1.6% | — |
| Paradigm Biocapital Advisors LP | $21.5M | 900K | 1.6% | — |
| Jupiter Topco LLC | $17.7M | 750K | 1.3% | — |
| Price T Rowe Associates Inc | $15.7M | 659K | 1.1% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kardigan, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $90M 3 trades by 3 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $90M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Nelsen Robert Director | June 22, 2026 | Buy | 1,250,000 | $16.00 | $20M |
| Berns Paul L Director | June 22, 2026 | Buy | 1,250,000 | $16.00 | $20M |
| Hrtg Pv, L.P. 10% owner | June 22, 2026 | Buy | 3,125,000 | $16.00 | $50M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 11, 2026
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- S-1 S-1
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Kardigan, Inc. in brief
- What does Kardigan, Inc. do?
- Kardigan, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Kardigan, Inc.'s stock ticker?
- Kardigan, Inc. trades under the ticker KARD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Kardigan, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Hrtg Gpe, LLC, FMR LLC and Perceptive Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Kardigan, Inc. stock?
- Over the last 12 months, Kardigan, Inc.'s directors and officers reported 3 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
- When is Kardigan, Inc.'s next earnings date?
- Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kardigan, Inc. announces its own schedule.
Follow research on Kardigan, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.